ProCE Banner Activity

Reflexiones sobre las novedades sobre LLC y LCM presentadas en ASCO 2022

Clinical Thought
En este comentario, dos expertos hablan sobre los importantes ensayos clínicos recientes abordados en ASCO 2022 que podrían afectar al tratamiento de la leucemia linfocítica crónica y el linfoma de células del manto.

Released: July 12, 2022

Expiration: July 11, 2023

Share

Faculty

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD: consultant: AbbVie, AcertaPharma, ADCT Therapeutics, AstraZeneca, Celegene, Genentech, MEI, Morphosys, Pharmacyclics, Roche, TG Therapeutics.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: consultant: AbbVie, Acerta/AstraZeneca, Adaptive, AZ, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem; researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics.